Mylan Announces Tentative Approval for Terbinafine Hydrochloride Tablets

PITTSBURGH, April 15 /PRNewswire-FirstCall/ -- Mylan Laboratories Inc. (NYSE: MYL) today announced that the U.S. Food and Drug Administration has granted tentative approval for Mylan Pharmaceuticals Inc.'s Abbreviated New Drug Application for Terbinafine Hydrochloride Tablets, 250 mg. Terbinafine HCl Tablets are the generic version of Novartis Pharmaceuticals Corporation's Lamisil® Tablets, which have annual U.S. sales of approximately $655 million.

Mylan Laboratories Inc. is a leading pharmaceutical company with four subsidiaries, Mylan Pharmaceuticals Inc., Mylan Technologies Inc., UDL Laboratories Inc. and Mylan Bertek Pharmaceuticals Inc., that develop, license, manufacture, market and distribute an extensive line of generic and proprietary products.

For more information about Mylan, visit www.mylan.com .

SOURCE Mylan Laboratories Inc.
04/15/2005
CONTACT: Media, Heather Bresch, +1-724-514-1800, or Investors, Kris King, +1-724-514-1800, both of Mylan Laboratories Inc.
Web site: http://www.mylan.com